肿瘤治疗辅助用药阿瑞匹坦获批上市了

Neurokinin-1 (nk-1) receptor blockers developed by Merck can highly selectively block and bind to nk-1 receptors, thereby inhibiting vomiting caused by chemotherapy drugs. This drug is the first NK-1 receptor antagonist antiemetic drug approved in the global market, and also the first pitant drug marketed in China. It is used to prevent acute and delayed nausea and vomiting that continue to occur during the initial and repeated treatment of highly emetogenic anti-tumor drug chemotherapy.     

Aprepitant can cross the blood-brain barrier and occupy the NK-1 receptor in the brain with high selectivity and high affinity, thereby inhibiting the origin of CINV at the central level. It can be used to prevent acute and delayed nausea and vomiting that occur during the development of initial and repeated treatments with highly emetogenic antineoplastic chemotherapy.                                                      

Currently, aprepitant has been approved by the State Food and Drug Administration of China and is available on the market in China. As the world's first highly selective NK-1 receptor antagonist, aprepitant is expected to bring good news to the lives of Chinese chemotherapy patients. 

Aprepitant is a dose-dependent CYP3A4 inhibitor, and we must use it with caution when used in patients with drugs that can mainly be metabolized by CYP3A4;

1. When aprepitant is used together with warfarin, the international normalized ratio (INR) of partial prothrombin activity time can be significantly reduced. For patients requiring long-term warfarin therapy, INR should be monitored closely for two weeks after the three-day aspirin course at the beginning of each chemotherapy cycle, especially on days 7-10.

2. During the treatment period and within 28 days after taking aprepitant, the efficacy of sexual hormonal contraceptives can be significantly reduced in patients. Therefore, we should choose an alternative method of contraception or use a rescue method of contraception during aprepitant treatment and for one month after the last dose of aprepitant.    

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended hot articles: